Value-based Healthcare in Germany: From free price-setting to a regulated market

This report looks at the evolution of health technology assessment and pharmaceutical pricing reform in Germany and examines the new focus on providers and health outcomes.

Martin Koehring
Martin Koehring
Senior Manager for Sustainability, Climate Change and Natural Resources & Head of the World Ocean Initiative, Economist Enterprise

9 Sept 2015

Value-based Healthcare in Germany: From free price-setting to a regulated market

Value-based healthcare in Germany: From free price-setting to a regulated market is a report by The Economist Intelligence Unit (EIU), commissioned by Gilead Sciences. It looks at the evolution of health technology assessment and pharmaceutical pricing reform in Germany and examines the new focus on providers and health outcomes.

“The term ‘value-based healthcare’ doesn’t translate well into German,” says Dr Clemens Guth, executive director of Artemed, a private hospital and nursing-home operator in Germany, and co-author of a book on value-based healthcare in Germany with Michael Porter, a Harvard University professor who coined the term. Value-based healthcare looks at health outcomes of treatment relative to cost.

Nevertheless, there are signs that the government is trying to evaluate health outcomes. Some of the most controversial reforms in recent years have involved the assessment and pricing of pharmaceutical products, the reverberations of which are still being felt in the German drug market. In 2011 Germany imposed maximum reimbursement prices for all new reimbursable treatments following the assessment of their added therapeutic value. This put an end to the free pricing era in Germany.

Further reading:


Value-based healthcare in the UK: A system of trial and error
Supported by Gilead and Kite

Value-based healthcare in the UK: A system of trial and error

This Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the UK healthcare system.

Value-based healthcare in Portugal: Necessity is the mother of invention
Supported by Gilead and Kite

Value-based healthcare in Portugal: Necessity is the mother of invention

This paper examines how the recent economic crisis has shaped health technology assessment; the role of the hospital sector; and promising initiatives in integrated care, family health units and a new process for the re-evaluation of health technologies.

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria
Supported by Gilead and Kite

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria

This new Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price neg

Value-based healthcare in Spain: Regional experimentation in a shared governance setting
Supported by Gilead and Kite

Value-based healthcare in Spain: Regional experimentation in a shared governance setting

Value-based healthcare in Spain is an Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences. It looks at health outcomes of treatment relative to cost and at the structure of Spanish healthcare delivery.